公开(公告)号：US11634497B2

公开(公告)日：2023-04-25

申请号：US16482173

申请日：2018-02-01

Applicant: NOVARTIS AG

Inventor： Steven Bender ,  Tracy Charlton ,  Anna Galkin ,  Bernhard Hubert Geierstanger ,  Scott Martin Glaser ,  Shailaja Kasibhatla ,  Mark Knuth ,  Sabine Rottmann ,  Sarah Rue ,  Glen Spraggon ,  Tetsuo Uno

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00

Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US12180291B2

公开(公告)日：2024-12-31

申请号：US18164519

申请日：2023-02-03

Applicant: Novartis AG

Inventor： Steven Bender ,  Tracy Charlton ,  Anna Galkin ,  Bernhard Hubert Geierstanger ,  Scott Martin Glaser ,  Shailaja Kasibhatla ,  Mark Knuth ,  Sabine Rottmann ,  Sarah Rue ,  Glen Spraggon ,  Tetsuo Uno

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00

Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US20210155713A1

公开(公告)日：2021-05-27

申请号：US17058870

申请日：2019-05-29

Applicant: Novartis AG

Inventor： Michael DIDONATO ,  Christoph ERKEL ,  Anna Galkin ,  Scott GLASER ,  Klaus Felix HARTLEPP ,  Yong JIA ,  Alexandra KRAUS ,  Christian Cho-Hua LEE ,  Sarah Michelle RUE ,  Jian SHI ,  Xenia Karola WEZLER

IPC: C07K16/40 ,  A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

公开(公告)号：US20220340685A1

公开(公告)日：2022-10-27

申请号：US17642766

申请日：2020-09-17

Applicant: Novartis AG

Inventor： Michael DiDonato ,  Mirek Dostalek ,  Christoph Erkel ,  Javier Estrada Diez ,  Anna Galkin ,  Scott Martin Glaser ,  Klaus Felix Hartlepp ,  Yong Jia ,  Deborah A. Knee ,  Alexandra Kraus ,  Christian Cho-Hua Lee ,  Luigi Manenti ,  Sarah Michelle Rue ,  Jian Shi ,  Xenia Karola Wezler ,  Gabrielle Wong

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/22 ,  A61P35/00

Abstract: Provided herein are combinations comprising an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to ENTPD2 (e.g., human ENTPD2 protein), and an antibody or antigen-binding fragment thereof, e.g., a monoclonal antibody or antigen binding fragment thereof, that specifically binds to CD73 (e.g., human CD73 protein), and methods of using these combinations.

公开(公告)号：US20240336701A1

公开(公告)日：2024-10-10

申请号：US18427264

申请日：2024-01-30

Applicant: Novartis AG

Inventor： Michael DIDONATO ,  Christoph ERKEL ,  Anna Galkin ,  Scott Martin GLASER ,  Klaus Felix HARTLEPP ,  Yong JIA ,  Alexandra KRAUS ,  Christian Cho-Hua LEE ,  Sarah Michelle RUE ,  Jian SHI ,  Xenia Karola WEZLER

IPC: C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/40 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/92

Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

公开(公告)号：US11939397B2

公开(公告)日：2024-03-26

申请号：US17058870

申请日：2019-05-29

Applicant: Novartis AG

Inventor： Michael Didonato ,  Christoph Erkel ,  Anna Galkin ,  Scott Glaser ,  Klaus Felix Hartlepp ,  Yong Jia ,  Alexandra Kraus ,  Christian Cho-Hua Lee ,  Sarah Michelle Rue ,  Jian Shi ,  Xenia Karola Wezler

IPC: C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/40 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/92

Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

公开(公告)号：US20220348651A1

公开(公告)日：2022-11-03

申请号：US17642763

申请日：2020-09-17

Applicant: Novartis AG

Inventor： Michael DiDonato ,  Mirek Dostalek ,  Christoph Erkel ,  Javier Estrada Diez ,  Anna Galkin ,  Scott Martin Glaser ,  Klaus Felix Hartlepp ,  Yong Jia ,  Deborah A. Knee ,  Alexandra Kraus ,  Christian Cho-Hua Lee ,  Luigi Manenti ,  Sarah Michelle Rue ,  Jian Shi ,  Xenia Karola Wezler ,  Gabrielle Wong

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

Abstract: Provided herein are methods of treating cancer using an antibody or antigen-binding fragments thereof that specifically bind to human ENTPD2 protein, and compositions comprising these antibodies or antigen-binding fragments for use in the treatment of cancer. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.